The U.S. Food and Drug Administration (FDA) recently approved Tyruko (natalizumab-sztn, made by Sandoz, a division of the Novartis group). Tyruko is the first biosimilar disease-modifying therapy (DMT) for individuals…
Read More
MS Awareness Month is an opportunity to draw attention to our MS community and help educate others about what it means to live with multiple sclerosis. Over the years that’s…
By Pete Broderick | Since the mid-1990s, disease modifying therapies (DMTs) have been our first line interventions in the fight against MS. But what exactly do we mean by “DMT,”…
There’s a fundamental difference in opinion in modern MS treatment. On one hand, we have a treatment strategy defined by what amounts to a “wait and see” approach. In this…
One of the most difficult decisions for someone who’s been living with MS for a long time is whether or not to discontinue their treatment with disease modifying therapies (DMTs)….
This issue of InforMS describes the serious efforts of expert physicians to identify the best strategies to treat people with multiple sclerosis. Unfortunately, however, there is another critical decision maker…
Join RMMSC Medical Director Dr. Timothy Vollmer for an in-depth look at disease modifying therapies (DMTs) – the front line in our fight against MS. This webinar will give you…
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Enrique Alvarez answers some common questions on…
The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Timothy Vollmer answers some common questions on…